Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rezolute, Inc. (RZLT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.4900+0.2600 (+8.05%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.2300
Open3.3950
Bid2.2800 x 800
Ask4.3800 x 1000
Day's Range3.2200 - 3.5500
52 Week Range2.2600 - 13.0830
Volume5,612
Avg. Volume92,679
Market Cap53.886M
Beta (5Y Monthly)3.62
PE Ratio (TTM)N/A
EPS (TTM)-3.0140
Earnings DateFeb 08, 2022 - Feb 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.80
  • GlobeNewswire

    Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

    REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer. Dr. Roberts joined Rezolute in 2017 as Vice President of Clinical Developm

  • GlobeNewswire

    Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

    Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75% at anticipated therapeutic doses Positive data from Phase 1b multiple-ascending dose study of RZ402 enable Phase 2 proof-of-concept study initiation later this year REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinic

  • GlobeNewswire

    Rezolute to Host Corporate Update Call on May 4, 2022

    Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ETREDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that management will be hosting a corporate update call. The call will highlight recent pipeline advancements and continued

Advertisement
Advertisement